References
- Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study of the Group d'Etude des Lymphomes de L'Adulte. J Clin Oncol 2005; 23: 4117–4118
- Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, , for the MabThera International Trial (MinT) Group, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
- Kaplan L D, Lee J Y, Ambinder R F, Sparano J A, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106: 1538–1543
- Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, , German Low-Grade Lymphoma Study Group, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071
- van Oers M H, Klasa R, Marcus R E, Wolf M, Kimby E, Gascoyne R D, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III Intergroup trial. Blood 2006, Epub ahead of print, July 27
- Kewalramani T, Zelenetz A D, Nimer S D, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3685
- May, et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma 2006; 47: 2559–2567
- Alas S, Ng C P, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res 2002; 8: 836–845
- Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001; 61: 5137–5144
- Jazirehi A R, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-kB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65: 264–276
- Crump M, Shepherd L, Lin B. A randomized phase III study of gemcitabine, dexamethasone and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive B-cell and T-cell non-Hodgkin's lymphoma. Clin Lymphoma 2005; 6: 56–60
- Hagberg H, Gisselbrecht C. Randomized phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomization to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006; 17(Suppl 4)31–32